Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study
The LancetPublished 1 July 2005
Jonathan A C Sterne, Miguel A. Hernán, Bruno Ledergerber, Kate Tilling, Rainer Weber, Pedram Sendi
Citations558
SJR quartileQ1
SJR score12.11
SNIP22.72
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The results, which are appropriately controlled for confounding by indication, are consistent with reported declines in rates of AIDS and death in developed countries, and provide a context in which to consider adverse effects of HAART.
Abstract
Our results, which are appropriately controlled for confounding by indication, are consistent with reported declines in rates of AIDS and death in developed countries, and provide a context in which to consider adverse effects of HAART.
Keywords
Immunology and MicrobiologyMedicine
New England Journal of MedicineDeclining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
9,465 Citations1998Frank J. Palella, Kathleen M. Delaney +6 more
The recent declines in morbidity and mortality due to AIDS are attributable to the use of more intensive antiretroviral therapies.
EpidemiologyMarginal Structural Models and Causal Inference in Epidemiology
5,548 Citations2000James M. Robins, Miguel A. Hernán +1 more
Clinical Infectious Diseases1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults
4,356 Citations1993K. G. Castro, Jill Ward +5 more
The classification system for HIV infection is revised to emphasize the clinical importance of the CD4+ T-lymphocyte count in the categorization of HIV-related clinical conditions and the AIDS surveillance case definition is expanded.
New England Journal of MedicineA Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
2,666 Citations1997Scott M. Hammer, Kathleen Squires +14 more
Treatment with indinavir, zidovudine, and lamivudine as compared with zidvudine and lam ivudine alone significantly slows the progression of HIV-1 disease in patients with 200 CD4 cells or fewer per cubic millimeter and prior exposure to zidavudine.
EpidemiologyA Structural Approach to Selection Bias
2,630 Citations2004Miguel A. Hernán, Sonia Hernández–Dı́az +1 more
This work argues that the causal structure underlying the bias in each example is essentially the same: conditioning on a common effect of 2 variables, one of which is either exposure or a cause of exposure and the other is either the outcome or acause of the outcome.
EpidemiologyMarginal Structural Models to Estimate the Causal Effect of Zidovudine on the Survival of HIV-Positive Men
1,727 Citations2000Miguel A. Hernán, Babette Brumback +1 more
The marginal structural Cox proportional hazards model is described and used to estimate the causal effect of zidovudine on the survival of human immunodeficiency virus-positive men participating in the Multicenter AIDS Cohort Study.
New England Journal of MedicineCombination Antiretroviral Therapy and the Risk of Myocardial Infarction
1,665 Citations2003Nina Friis‐Møller, Caroline Sabin
Combination antiretroviral therapy was independently associated with a 26 percent relative increase in the rate of myocardial infarction per year of exposure during the first four to six years of use, however, the absolute risk of my Cardiac Infarction was low and must be balanced against the marked benefits from antireTroviral treatment.
The LancetPrognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
1,524 Citations2002Matthias Egger, Margaret May +17 more
The CD4 cell count at initiation was the dominant prognostic factor in patients starting HAART, and should be taken into account in future treatment guidelines.
The LancetChanging patterns of mortality across Europe in patients infected with HIV-1
1,284 Citations1998Amanda Mocroft, Stefano Vella +9 more
Death rates across Europe among patients infected with HIV-1 have been falling since September, 1995, and at the beginning of 1998 were less than a fifth of their previous level.
The LancetDecline in the AIDS and death rates in the EuroSIDA study: an observational study
1,239 Citations2003Amanda Mocroft, Bruno Ledergerber +8 more
The initial drop in mortality and morbidity after the introduction of HAART has been sustained and potential long-term adverse effects associated with HAART have not altered its effectiveness in treating AIDS.
American Journal of EpidemiologyTHE MULTICENTER AIDS COHORT STUDY: RATIONALE, ORGANIZATION, AND SELECTED CHARACTERISTICS OF THE PARTICIPANTS
1,200 Citations1987Richard A. Kaslow, David G. Ostrow +4 more
The Multicenter AIDS Cohort Study was designed to elucidate the natural history of the infection causing acquired immunodeficiency syndrome (AIDS), identify risk factors for occurrence and clinical expression of the virus, and establish a repository of biologic specimens for future study.
The LancetMethotrexate and mortality in patients with rheumatoid arthritis: a prospective study
1,110 Citations2002Hyon K. Choi, Miguel A. Hernán +3 more
The data indicate that methotrexate may provide a substantial survival benefit, largely by reducing cardiovascular mortality, which would set a standard against which new disease-modifying antirheumatic drugs could be compared.
The LancetClinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
933 Citations1999Bruno Ledergerber, Matthias Egger +10 more
The rate of virological failure of HAART was high among patients with a history of antiretroviral treatment, but the probability of clinical progression was low even in patients with viral rebound.
The LancetClinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study
901 Citations2000Gilbert Greub, B Ledergerber +13 more
Hematitis C virus and active intravenous drug use could be important factors in the morbidity and mortality among HIV-1-infected patients, possibly through impaired CD4-cell recovery in HCV seropositive patients receiving potent antiretroviral therapy.
EpidemiologyThe Womenʼs Interagency HIV Study
829 Citations1998Susan E. Barkan, Sandra Melnick +8 more
The Women's Interagency HIV Study comprises the largest U.S. cohort to date of HIV-seropositive and high-risk seronegative women and represents a rich opportunity for future studies of HIV disease progression and pathogenesis.
BMJFetal origins of adult disease---the hypothesis revisited
799 Citations1999Alan Lucas, Mary Fewtrell +1 more
The hypothesis that adult disease has fetal origins is plausible, but much supportive evidence is flawed by incomplete and incorrect statistical interpretation.
Statistics in MedicineRelation of pooled logistic regression to time dependent cox regression analysis: The framingham heart study
792 Citations1990Ralph B. D’Agostino, Mei‐Ling Ting Lee +4 more
Numerical examples covering a variety of sample sizes and proportions of events display the closeness of this relationship in situations typical of the Framingham Study.
EpidemiologyDo We Still Need a Cohort Study of Women with HIV Infection?
731 Citations1998Susan E. Barkan
The Women's Interagency HIV Study comprises the largest U.S. cohort to date of HIV-seropositive and high-risk seronegative women and represents a rich opportunity for future studies of HIV disease progression and pathogenesis.
BMJImpact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study
624 Citations1997Matthias Egger, Bernard Hirschel +8 more
The introduction of antiretroviral combination therapies outside the selected patient groups included in clinical trials has led to comparable reductions in disease progression and mortality in Switzerland.
The LancetRandomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
540 Citations1998D. William Cameron, Margo Heath‐Chiozzi +9 more
Although earlier intervention with combination therapy may provide much more effective treatment, ritonavir in patients with advanced disease and extensive previous antiretroviral use is safe and effective, lowers the risk of AIDS complications, and prolongs survival.
Journal of the American Statistical AssociationMarginal Structural Models to Estimate the Joint Causal Effect of Nonrandomized Treatments
504 Citations2001Miguel A. Hernán, Babette Brumback +1 more
A marginal structural Cox proportional hazards model is used to estimate the joint effect of zidovudine (AZT) and prophylaxis therapy for Pneumocystis carinii pneumonia on the survival of HIV-positive men in the Multicenter AIDS Cohort Study, an observational study of homosexual men.
Annals of Internal MedicineEffect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 × 10<sup>9</sup> cells/L
363 Citations2003Evan Wood, Robert S. Hogg +4 more
The effect of baseline CD4+ cell count and adherence on survival rates after the initiation of HAART was evaluated and it was suggested that delaying HAART after the CD4- cell count declines below 0.350 109 cells/L may be unsafe.
PubMedImproved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.
324 Citations1999Robert S. Hogg, Benita Yip +5 more
This population-based cohort study confirms that patients initially treated with a triple-drug antiretroviral regimen comprising 2 NRTIs plus protease inhibitor or a non-NRTI have a lower risk of morbidity and death than patients treated exclusively with 2 N RTIs.
The Journal of Infectious DiseasesCombination Antiretroviral Therapy and Recent Declines in AIDS Incidence and Mortality
279 Citations1999Eric Vittinghoff, Susan Scheer +4 more
Declines in incidence of HIV infection, changes in HIV virulence, and end-point underreporting cannot fully explain the decline in AIDS and death in 1996, but the introduction of combination antiretroviral therapy as the standard of care may already have had measurable effects.
The Stata Journal Promoting communications on statistics and StataControlling for Time-dependent Confounding using Marginal Structural Models
268 Citations2004Zoe Fewell, Miguel A. Hernán +4 more
The use of marginal structural models are described to estimate the effect of methotrexate on mortality in persons suffering from rheumatoid arthritis and the method is based on deriving inverse-probability-of-treatment weights, which are then used in a pooled logistic regression model to estimates the causal effect of treatment on outcome.
American Journal of EpidemiologyEffect of Highly Active Antiretroviral Therapy on Time to Acquired Immunodeficiency Syndrome or Death using Marginal Structural Models
266 Citations2003Stephen R. Cole
To estimate the net effect of highly active antiretroviral therapy (HAART) on time to acquired immunodeficiency syndrome (AIDS) or death, the authors used inverse probability-of-treatment weighted estimation of a marginal structural model, which can appropriately adjust for time-varying confounders affected by prior treatment or exposure.
The LancetHIV prevention before HAART in sub-Saharan Africa
232 Citations2002Elliot Marseille, Paul Hofmann +1 more
It is shown that funding HAART at the expense of prevention means greater loss of life, and to maximise health benefits, the next major increments of HIV funding in sub-Saharan Africa should be devoted mainly to prevention and to some non-HAART treatment and care.
Sozial- und PräventivmedizinThe Swiss HIV Cohort Study: Rationale, organization and selected baseline characteristics
148 Citations1994the Swiss HIV Cohort Study (SHCS), Bruno Ledergerber +3 more
The SHCS serves multiple purposes as a research project, as infrastructure for multidisciplinary research and as a tool to improve patient care as well as several international and national trials, post-marketing surveillances and expanded access protocols were or still are based upon its infrastructure.
AIDSIncreasing survival time after AIDS in Italy: the role of new combination antiretroviral therapies
140 Citations1999Patrizio Pezzotti, Pier Angela Napoli +5 more
AIDSUse of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials
139 Citations1999Andrew Phillips, Sophie Grabar +4 more
Serious biases can be present when comparing outcomes from the use of antiretroviral regimens in observational studies, however, such bias is not inevitable and careful interpretation of the results from several observational studies considered together is likely to be informative, guiding the design of new trials.
American Journal of Public HealthImpact of the AIDS epidemic on morbidity and mortality among intravenous drug users in a New York City methadone maintenance program.
126 Citations1989Peter A. Selwyn, Diana Hartel +2 more
The data suggest that the AIDS epidemic has had a profound effect on patterns of morbidity and mortality among intravenous drug users in this methadone program population, and drug treatment programs may be important sites for targeting clinical services for drug users with AIDS.
BMJSystematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy
97 Citations2002Rachel Jordan, Lisa Gold +2 more
Evidence from randomised controlled trials supports the use of triple therapy but there is inadequate evidence for quadruple or higher combinations.
AIDS Research and Human RetrovirusesHuman Immunodeficiency Virus Type 1 RNA Level and CD4 Count as Prognostic Markers and Surrogate End Points: A Meta-Analysis
90 Citations2000
Change in HIV-1 RNA, particularly using AUCMB, and in CD4 count should be measured to aid patient management and evaluation of treatment activity in clinical trials because two randomized treatment comparisons may show similar differences between treatments in marker changes but not similar differences in progression to AIDS/death.
AIDSCD4 cell count as a surrogate endpoint in HIV clinical trials
75 Citations1998Michael D. Hughes, Michael J. Daniels +3 more
CD4 cell count is a weak surrogate endpoint, but has some value as an aid for screening treatments for drug development or preliminary regulatory approval, and other mechanisms of drug action not captured by initial change in CD4 cells are important.
AIDSImpact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland
50 Citations1998Martin Gebhardt, Martin Rickenbach +1 more
The introduction of antiretroviral combination therapies in a single cohort study explained 50% of the decline in national AIDS surveillance reports and must become an important component of AIDS surveillance systems.
Emerging infectious diseasesEpidemiology, Evolution, and Future of the HIV/AIDS Pandemic
25 Citations2001Bruce R. Levin, James J. Bull +1 more
This analysis suggests that if HIV chemotherapy reduces the transmissibility of the virus, treating individual patients can reduce the frequency of HIV infections and AIDS deaths in the general population.
New England Journal of MedicineHIV Drug Resistance — A Chink in the Armor
13 Citations2002Martin Hirsch
In the resource-rich countries, a remarkable success story has emerged during the past decade in the treatment of human immunodeficiency virus (HIV) infections, but the proportion of new HIV infections with some degree of drug resistance is increasing in North America.